Scientific Sessions 2024  /  Unbreak My Heart: Cardio-Oncology Across the Spectrum of Cardiovascular Disease  /  Stiffen Up: Evaluation of HFpEF in the Patient with Cancer
Logo

American Heart Association

  2
  0

Final ID:

Stiffen Up: Evaluation of HFpEF in the Patient with Cancer

  • Fontana, Marianna  ( Royal Free Hospital , London , United Kingdom )
  • Sarswat, Nitasha  ( University of Chicago , Chicago , Illinois , United States )
  • Ruberg, Frederick  ( Boston University , Boston , Massachusetts , United States )
    • Author Disclosures:
    Marianna Fontana: DO have relevant financial relationships ; Consultant:Dr. Fontana reports consultancy/advisory boards for Alnylam, Alexion/Caelum Biosciences, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Prothena, Pfizer, Novonordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astrazeneca, Pfizer. Salary from British Heart Foundation Intermediate Fellowship. Share options in LexeoTherapeutics and shares in Mycardium.:Active (exists now) | Nitasha Sarswat: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alexion:Active (exists now) ; Research Funding (PI or named investigator):BridgeBio:Active (exists now) ; Consultant:BridgeBio:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Astra Zeneca:Active (exists now) ; Research Funding (PI or named investigator):Alnylam:Active (exists now) ; Consultant:Alnylam:Active (exists now) | Frederick Ruberg: DO have relevant financial relationships ; Consultant:Attralus:Active (exists now) ; Research Funding (PI or named investigator):Akcea:Past (completed) ; Research Funding (PI or named investigator):Alnylam:Past (completed) ; Research Funding (PI or named investigator):Anumana:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Unbreak My Heart: Cardio-Oncology Across the Spectrum of Cardiovascular Disease

Sunday, 11/17/2024 , 03:30PM - 04:45PM

Cardiovascular Seminar

More abstracts on this topic:
Don't Let Up: An Ounce of Prevention is Worth a Pound in Cardio-Oncology

Watson Karol, Lloyd-jones Donald

Heating Up: Managing Arrhythmias in Patients with Cancer

Fradley Michael, Russo Andrea, Singh Jagmeet

More abstracts from these authors:
Emerging Clinical Landscape in ATTR-CM

Sarswat Nitasha

Meet the Trialist: Nexiguran ziclumeran (nex-z, also known as NTLA-2001), an investigational in vivo CRISPR-based therapy for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM): interim report of the Phase 1 study

Fontana Marianna

You have to be authorized to contact abstract author. Please, Login
Not Available